Cargando…
Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells. We hypothesized that serum PCSK9 levels would be associated with death and ICU ou...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234242/ https://www.ncbi.nlm.nih.gov/pubmed/35770004 http://dx.doi.org/10.3389/fmed.2022.876046 |
_version_ | 1784736023538827264 |
---|---|
author | Metkus, Thomas S. Kim, Bo Soo Jones, Steven R. Martin, Seth S. Schulman, Steven P. Leucker, Thorsten M. |
author_facet | Metkus, Thomas S. Kim, Bo Soo Jones, Steven R. Martin, Seth S. Schulman, Steven P. Leucker, Thorsten M. |
author_sort | Metkus, Thomas S. |
collection | PubMed |
description | BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells. We hypothesized that serum PCSK9 levels would be associated with death and ICU outcomes in patients with ARDS. METHODS: Using data and plasma samples from the NIH BioLINCC data repository, we assembled a cohort of 1,577 patients with the acute respiratory distress syndrome (ARDS) enrolled in two previously completed clinical trials, EDEN and SAILS. We measured PCSK9 levels in plasma within 24 h of intubation using commercially available ELISA kits (R&D Systems). We assessed the association of PCSK9 with mortality using Cox proportional hazard models. We also assessed clinical factors associated with PCSK9 level and the association of PCSK9 with the number of days free of mechanical ventilation and days free of ICU care. RESULTS: In 1,577 ARDS patients, median age was 53 years (IQR 42–65 years) and median APACHE III score 91 (72–111) connoting moderate critical illness. PCSK9 levels were 339.3 ng/mL (IQR 248.0–481.0). In multivariable models, race, cause of ARDS, body mass index, pre-existing liver disease, body temperature, sodium, white blood cell count and platelet count were associated with PCSK9 level. Presence of sepsis, use of vasopressors and ventilator parameters were not associated with PCSK9 level. PCSK9 levels were not associated with in-hospital mortality (HR per IQR 0.96, 95% CI 0.84–1.08, P = 0.47). Higher PCSK9 levels were associated with fewer ICU and ventilator free days. CONCLUSIONS: Plasma PCSK9 is not associated with mortality in ARDS, however higher PCSK9 levels are associated with secondary outcomes of fewer ICU free and ventilator free days. Clinical factors associated with PCSK9 in ARDS are largely unmodifiable. Further research to define the mechanism of this association is warranted. |
format | Online Article Text |
id | pubmed-9234242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92342422022-06-28 Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome Metkus, Thomas S. Kim, Bo Soo Jones, Steven R. Martin, Seth S. Schulman, Steven P. Leucker, Thorsten M. Front Med (Lausanne) Medicine BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells. We hypothesized that serum PCSK9 levels would be associated with death and ICU outcomes in patients with ARDS. METHODS: Using data and plasma samples from the NIH BioLINCC data repository, we assembled a cohort of 1,577 patients with the acute respiratory distress syndrome (ARDS) enrolled in two previously completed clinical trials, EDEN and SAILS. We measured PCSK9 levels in plasma within 24 h of intubation using commercially available ELISA kits (R&D Systems). We assessed the association of PCSK9 with mortality using Cox proportional hazard models. We also assessed clinical factors associated with PCSK9 level and the association of PCSK9 with the number of days free of mechanical ventilation and days free of ICU care. RESULTS: In 1,577 ARDS patients, median age was 53 years (IQR 42–65 years) and median APACHE III score 91 (72–111) connoting moderate critical illness. PCSK9 levels were 339.3 ng/mL (IQR 248.0–481.0). In multivariable models, race, cause of ARDS, body mass index, pre-existing liver disease, body temperature, sodium, white blood cell count and platelet count were associated with PCSK9 level. Presence of sepsis, use of vasopressors and ventilator parameters were not associated with PCSK9 level. PCSK9 levels were not associated with in-hospital mortality (HR per IQR 0.96, 95% CI 0.84–1.08, P = 0.47). Higher PCSK9 levels were associated with fewer ICU and ventilator free days. CONCLUSIONS: Plasma PCSK9 is not associated with mortality in ARDS, however higher PCSK9 levels are associated with secondary outcomes of fewer ICU free and ventilator free days. Clinical factors associated with PCSK9 in ARDS are largely unmodifiable. Further research to define the mechanism of this association is warranted. Frontiers Media S.A. 2022-06-13 /pmc/articles/PMC9234242/ /pubmed/35770004 http://dx.doi.org/10.3389/fmed.2022.876046 Text en Copyright © 2022 Metkus, Kim, Jones, Martin, Schulman and Leucker. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Metkus, Thomas S. Kim, Bo Soo Jones, Steven R. Martin, Seth S. Schulman, Steven P. Leucker, Thorsten M. Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome |
title | Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome |
title_full | Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome |
title_fullStr | Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome |
title_full_unstemmed | Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome |
title_short | Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome |
title_sort | plasma proprotein convertase subtilisin/kexin type 9 (pcsk9) in the acute respiratory distress syndrome |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234242/ https://www.ncbi.nlm.nih.gov/pubmed/35770004 http://dx.doi.org/10.3389/fmed.2022.876046 |
work_keys_str_mv | AT metkusthomass plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome AT kimbosoo plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome AT jonesstevenr plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome AT martinseths plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome AT schulmanstevenp plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome AT leuckerthorstenm plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome |